Jun Cao

Jun Cao


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LMLili Mao
Lili Mao
MFMeiyu Fang
Meiyu Fang
YCYu Chen
Yu Chen
XWXiaoting Wei
Xiaoting Wei
JCJun Cao
Jun Cao
LSLu Si
Lu Si
Purpose: Anti–programmed cell death-1 monotherapy is part of standard therapy for cutaneous melanoma but has low efficacy in mucosal melanoma. We evaluated the efficacy and safety of atezolizumab plus bevacizumab as first-line therapy for advanced mucosal melanoma. Patients and Methods: This multicenter, open-label, single-arm, phase II study used a Simon's two-stage design. Atezolizumab (fixed-dose, 1,200 mg) and bevacizumab (7.5 mg/kg) were administered by intravenous infusion every 3 weeks. The primary endpoint was objective response rate (ORR), determined per RECIST v1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety, with adverse events (AE) summarized using NCI-CTCAE v5.0. Results: Overall, 43 patients were enrolled, including 20 (46.5%) with unresectable and 23 (53.5%) with metastatic mucosal melanoma. Median follow-up was 13.4 months at data cutoff (July 30, 2021). Forty patients were evaluable for response: ORR was 45.0% [95% confidence interval (CI), 29.3%–61.5%; one complete response, 17 partial responses]. Median PFS was 8.2 months (95% CI, 2.7–9.6); 6- and 12-month PFS rates were 53.4% (95% CI, 36.6%–67.6%) and 28.1% (95% CI, 14.2%–43.9%), respectively. Median OS was not reached (NR; 95% CI, 14.4–NR). Six- and 12-month OS rates were 92.5% (95% CI, 78.5%–97.5%) and 76.0% (95% CI, 57.1%–87.5%), respectively. Median DOR was 12.5 months (95% CI, 5.5–NR). Overall, 90.7% (39/43) of patients experienced treatment-related AEs; 25.6% (11/43) experienced grade ≥3 events. Conclusions: Atezolizumab in combination with bevacizumab showed promising efficacy and manageable safety in patients with advanced mucosal melanoma.

29 May 2023 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
EYEnyu Yang
Enyu Yang
QDQianyun Ding
Qianyun Ding
XFXiaowei Fan
Xiaowei Fan
HYHaihan Ye
Haihan Ye
CXCheng Xuan
Cheng Xuan
XDXianfeng Ding
Xianfeng Ding

1 November 2019 in Medicine
Verified
Journal Article
Open access
ZWZhi-Hong Wu
Zhi-Hong Wu
JDJin-Yao Dai
Jin-Yao Dai
JSJia-Ni Shi
Jia-Ni Shi
MFMei-Yu Fang
Mei-Yu Fang
JCJun Cao
Jun Cao
For chondrosarcoma, metastasis to the thyroid gland is extremely rare. The diagnosis and treatment of thyroid metastasis from chondrosarcoma are discussed here.We found a case of thyroid malignancy occurring after treatment of chondrosarcoma. We reviewed patient characteristics, histological presentations on initial chondrosarcoma and thyroid metastasis, treatments, times of recurrence and death. In addition, we searched Embase, PubMed, and ISI Web of Science databases (1996–2018) for articles published in the English language using the key words “chondrosarcoma” and “thyroid” and we reviewed almost all the reports about thyroid metastasis from chondrosarcoma.Only 5 cases of chondrosarcoma metastases in the thyroid gland have been reported in the literature. We found that most patients are adults, with compression signs or pain, most of whom have poor prognoses. The main examinations are ultrasound, CT and fine needle aspiration biopsy, and primary treatment is surgery.These rare cases of chondrosarcoma presenting as a metastasis in the thyroid gland highlight the importance of close communication between radiologists, histopathologists, and clinicians to ensure that such exceptional cases are not missed.

11 June 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CFChenyan Fang
Chenyan Fang
XZXiaoting Zeng
Xiaoting Zeng
QJQing Ji
Qing Ji
TZTao Zhu
Tao Zhu
MFMeiyu Fang
Meiyu Fang
JCJun Cao
Jun Cao
Background: Angiosarcoma is a rare, aggressive soft tissue sarcoma characterized by poor prognosis and limited treatment consensus. Our aim was to clarify the clinicopathological features, treatment outcomes, and prognostic factors of these patients to inform improved management and follow-up strategies. Methods: We retrospectively analyzed the clinical, pathological, treatment, and survival data of patients with angiosarcoma treated from 2003 to 2024 at Zhejiang Cancer Hospital. Results: A total of 128 angiosarcoma patients were included, categorized as cutaneous (n = 49), visceral (n = 35), deep soft tissue (n = 31), breast (n = 10), and bone (n = 3). The median progression-free survival (PFS) and overall survival (OS) were 7 and 20 months, respectively, with 2-year PFS of 21.4% and 5-year OS of 29.6%. Superficial cases had better outcomes compared to deep-seated cases, larger tumors (> 5 cm) and distant metastases predicted worse prognosis. Primary surgery improved survival in localized disease, with adjuvant radiotherapy enhancing local control but not OS. In metastatic cases, first-line systemic therapies showed that paclitaxel-based regimens were less effective than doxorubicin-based chemotherapy, and the addition of anti-angiogenic therapy did not improve outcomes. Conclusion: This study underscores the heterogeneity of angiosarcoma across different sites, emphasizing the role of surgery for localized AS, and chemotherapy remains the mainstay for advanced cases. Targeted therapies and immunotherapies offer novel promise, especially the combination strategies.

20 April 2023 in Cancer Medicine
Verified
Journal Article
Open access
KCKeyu Chen
Keyu Chen
JXJiaojiao Xu
Jiaojiao Xu
WWWei Wang
Wei Wang
RJRuiyuan Jiang
Ruiyuan Jiang
HZHuanping Zhang
Huanping Zhang
MFMeiyu Fang
Meiyu Fang
Purpose: Phyllodes tumors (PTs) are rare neoplasms with a certain risk of recurrence and/or metastasis. In clinical practice, there is a lack of high‐quality clinical studies and unified guidelines to guide the treatment.Materials and Methods: All malignant and recurrence/metastasis PTs were retrospectively collected, which were diagnosed from 2008 to 2022.Results: A total of 82 patients were enrolled, including 69 malignant and 13 borderline tumors. 96.3% (79/82) received surgical treatment. During a median follow‐up of 55.5 months, 20 patients (20/82, 24.4%) had distant metastasis (DM), while 32 (32/82, 39.0%) had local recurrence (LR). Univariate analysis showed the survival of PTs was associated with surgical methods (p < 0.001), tumor size (p = 0.026), and biological behavior (p = 0.017), but not age at diagnosis. In relapsed borderline PTs, we did not find deaths due to disease progression. Patients with DM were all malignant PTs, with disease‐progression occurring within 3 years in more than 80% of patients. Among salvage treatments, the combination of antiangiogenic drugs improved the prognosis to some extent, with a significant increase in mPFS (2.77 vs. 1.53 months), but no significant statistical results were obtained (p = 0.168). Lactate dehydrogenase (LDH) was an independent predictor of the prognosis for malignant PTs (p = 0.001, HR = 1.203, 95%CI, 1.082–1.336).Conclusion: Borderline PTs rarely metastasize, and even if LR occurs, surgical resection can lead to long‐term survival. In metastatic phyllodes tumors (MPT), systemic therapy is not effective, but antiangiogenic drugs may prolong survival. LDH is an independent prognostic factor for malignant PTs to identify high‐risk tumors.

15 February 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
EYEnyu Yang
Enyu Yang
XFXiaowei Fan
Xiaowei Fan
HYHaihan Ye
Haihan Ye
XSXiaoyang Sun
Xiaoyang Sun
QJQing Ji
Qing Ji
JCJun Cao
Jun Cao
UBXD family (UBXDF), a group of proteins containing ubiquitin regulatory X (UBX) domains, play a crucial role in the imbalance of proliferation and apoptotic in cancer. In this study, we summarised bioinformatics proof on multi-omics databases and literature on UBXDF’s effects on cancer. Bioinformatics analysis revealed that Fas-associated factor 1 (FAF1) has the largest number of gene alterations in the UBXD family and has been linked to survival and cancer progression in many cancers. UBXDF may affect tumour microenvironment (TME) and drugtherapy and should be investigated in the future. We also summarised the experimental evidence of the mechanism of UBXDF in cancer, both in vitro and in vivo, as well as its application in clinical and targeted drugs. We compared bioinformatics and literature to provide a multi-omics insight into UBXDF in cancers, review proof and mechanism of UBXDF effects on cancers, and prospect future research directions in-depth. We hope that this paper will be helpful for direct cancer-related UBXDF studies.